HUP0102239A2 - Terfenadin metabolitokat és leukotrién inhibitorokat tartalmazó gyógyásszati készítmények - Google Patents

Terfenadin metabolitokat és leukotrién inhibitorokat tartalmazó gyógyásszati készítmények

Info

Publication number
HUP0102239A2
HUP0102239A2 HU0102239A HUP0102239A HUP0102239A2 HU P0102239 A2 HUP0102239 A2 HU P0102239A2 HU 0102239 A HU0102239 A HU 0102239A HU P0102239 A HUP0102239 A HU P0102239A HU P0102239 A2 HUP0102239 A2 HU P0102239A2
Authority
HU
Hungary
Prior art keywords
phenyl
leukotriene inhibitors
combination
pharmaceutical compositions
propyl
Prior art date
Application number
HU0102239A
Other languages
English (en)
Inventor
Paul D. Rubin
Original Assignee
Sepracor Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sepracor Inc. filed Critical Sepracor Inc.
Publication of HUP0102239A2 publication Critical patent/HUP0102239A2/hu
Publication of HUP0102239A3 publication Critical patent/HUP0102239A3/hu
Publication of HU228035B1 publication Critical patent/HU228035B1/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

A találmány tárgyát asztma, allergiás állapotok és gyulladás esetébenhatásos, antihisztaminokat és leukotriéninhibitorokat tartalmazókészítmények és ezek alkalmazása képezi. Az antihisztamin hatásúkomponens a terfenadin, a H1-hisztamin-receptor fehérjeantagonistája,amely a szokásos antihisztaminok által blokkolt választ továbbítja.Metabolitjai, például a fexofenadin - 4-/1-hidroxi-4-(4-hidroxi-difenil-metil-1-piperidinil)-butil/-a,a-dimetil-fenil-ecetsav -ugyancsak antihisztaminaktivitással rendelkeznek és a készítményekbenalkalmazhatók. A leukotriéninhibitorok közé tartozik például anátrium-1-/R-(3-(2-(6,7-difluor-2-kinolinil)-etinil)-fenil)-3-/2-(2-hidroxi-2-propil)-fenil/-tiometil-ciklopropán-acetát és az 1-/R-(3-(2-(2,3-diklór-tieno/3,2-b/piridin-5-il)-(E)-etenil)-fenil)-3-(2-(1-hidroxi-1-metil-etil)-fenil)-propil)-tiometi )-ciklopropán-ecetsavvagy sója. Ó
HU0102239A 1998-04-14 1999-04-13 Pharmaceutical compositions using terfenadine metabolites in combination with leukotriene inhibitors HU228035B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/059,570 US6194431B1 (en) 1998-04-14 1998-04-14 Methods and compositions using terfenadine metabolites in combination with leukotriene inhibitors
PCT/US1999/008077 WO1999052554A1 (en) 1998-04-14 1999-04-13 Methods and compositions using terfenadine metabolites in combination with leukotriene inhibitors

Publications (3)

Publication Number Publication Date
HUP0102239A2 true HUP0102239A2 (hu) 2002-03-28
HUP0102239A3 HUP0102239A3 (en) 2002-06-28
HU228035B1 HU228035B1 (en) 2012-08-28

Family

ID=22023833

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0102239A HU228035B1 (en) 1998-04-14 1999-04-13 Pharmaceutical compositions using terfenadine metabolites in combination with leukotriene inhibitors

Country Status (21)

Country Link
US (4) US6194431B1 (hu)
EP (2) EP1071463B1 (hu)
JP (1) JP2002511426A (hu)
KR (1) KR100686297B1 (hu)
CN (2) CN1768749A (hu)
AT (1) ATE328608T1 (hu)
AU (1) AU763979B2 (hu)
BR (1) BR9909641A (hu)
CA (1) CA2328074C (hu)
CY (1) CY1106800T1 (hu)
DE (1) DE69931771T2 (hu)
DK (1) DK1071463T3 (hu)
ES (1) ES2260910T3 (hu)
HU (1) HU228035B1 (hu)
IL (2) IL138993A0 (hu)
NO (1) NO20005147L (hu)
NZ (1) NZ507762A (hu)
PL (1) PL343526A1 (hu)
PT (1) PT1071463E (hu)
WO (1) WO1999052554A1 (hu)
ZA (1) ZA200005553B (hu)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6194431B1 (en) 1998-04-14 2001-02-27 Paul D. Rubin Methods and compositions using terfenadine metabolites in combination with leukotriene inhibitors
US20020198246A1 (en) * 1998-09-30 2002-12-26 Ono Pharmaceutical Co., Ltd. Agent for preventing and/or treating sinusitis
DE10007203A1 (de) * 2000-02-17 2001-08-23 Asta Medica Ag Neue Kombination nichtsedierender Antihistaminika mit Substanzen, die die Leukotrienwirkung beeinflussen, zur Behandlung der Rhinitis/Konjunktivitis
US6440994B1 (en) 2000-03-29 2002-08-27 Richard J. Sanders, Jr. Method of treating acne
US20020198228A1 (en) * 2001-04-03 2002-12-26 Kaura Sita R. Composition and method for the treatment of respiratory desease
AU2003237253A1 (en) * 2002-05-29 2003-12-19 Aventis Pharmaceuticals Holdings Inc. Method of treating asthma using fexofenadine
US20040115647A1 (en) * 2002-12-12 2004-06-17 Paterson Thomas S. Apparatus and method for identifying biomarkers using a computer model
WO2009027852A2 (en) * 2007-08-28 2009-03-05 Agi Therapeutics, P.L.C. Methods and compositions for treating gastrointestinal conditions
WO2016011254A1 (en) * 2014-07-16 2016-01-21 Henry J. Legere Md, Pa Combinations of antihistamines and leukotriene antagonists and methods of use thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3878217A (en) 1972-01-28 1975-04-15 Richardson Merrell Inc Alpha-aryl-4-substituted piperidinoalkanol derivatives
US4254129A (en) 1979-04-10 1981-03-03 Richardson-Merrell Inc. Piperidine derivatives
US4783465A (en) 1984-04-09 1988-11-08 Analgesic Associates Cough/cold mixtures comprising non-sedating antihistamine drugs
US4552899A (en) 1984-04-09 1985-11-12 Analgesic Associates Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs
US4617407A (en) * 1984-08-30 1986-10-14 Merck Frosst Canada, Inc. Leukotriene antagonists
US4742175A (en) 1986-05-07 1988-05-03 Merrell Dow Pharmaceuticals Inc. Preparation of polymorphically pure terfenadine
US4800162A (en) 1987-04-01 1989-01-24 Sepracor, Inc. Method for resolution of steroisomers in multiphase and extractive membrane reactors
US4829064A (en) 1987-06-08 1989-05-09 Analgesic Associates Cough/cold mixtures comprising non-sedating antihistamine drugs
US4929605A (en) 1987-10-07 1990-05-29 Merrell Dow Pharmaceuticals Inc. Pharmaceutical composition for piperidinoalkanol derivatives
US4996061A (en) 1987-10-07 1991-02-26 Merrell Dow Pharmaceuticals Inc. Pharmaceutical composition for piperidinoalkanol-decongestant combination
CN1053570C (zh) 1987-10-07 2000-06-21 默尔多药物公司 哌啶子基链烷醇的药用组合物-减充血剂复方的制备方法
US5057427A (en) 1988-04-07 1991-10-15 Sepracor, Inc. Method for resolution of stereoisomers
US4990259A (en) 1988-12-16 1991-02-05 The Amalgamated Sugar Company Chromatographic separator sorbent bed preparation
US5019591A (en) 1989-02-17 1991-05-28 Pennsylvania Research Corporation Method for treating retinopathy and other small vessel disorders associated with diabetes
JPH07506828A (ja) 1992-05-11 1995-07-27 メレルダウファーマス−ティカルズ　インコーポレイテッド 肝臓が損われた患者での抗ヒスタミン剤としてのターフェナジン誘導体の用途
JP3041954B2 (ja) 1992-08-03 2000-05-15 セプラコア インコーポレーテッド アレルギー疾患治療用のテルフェナジン代謝物及びその光学的に純粋な異性体
AU670004B2 (en) 1993-06-24 1996-06-27 Albany Molecular Research, Inc. Piperidine derivatives and process for their production
WO1995010278A1 (en) 1993-10-15 1995-04-20 Hoechst Marion Roussel, Inc. Treatment of allergic disorders with terfenadine carboxylate
US5633272A (en) * 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
JPH11507670A (ja) * 1995-06-12 1999-07-06 ジー．ディー．サール アンド カンパニー シクロオキシゲナーゼ−２インヒビターと５−リポキシゲナーゼインヒビターの組合せによる炎症と炎症関連疾患の治療
CA2245162A1 (en) 1996-02-08 1997-08-14 Merck & Co., Inc. Method of treatment and pharmaceutical composition
ES2169351T3 (es) * 1996-02-13 2002-07-01 Searle & Co Combinaciones que tienen efectos inmunosupresores, que contienen inhibidores de ciclooxigenasa-2 y 5-lipoxigenasa.
US5919776A (en) * 1996-12-20 1999-07-06 Merck & Co., Inc. Substituted aminoquinolines as modulators of chemokine receptor activity
US5900421A (en) * 1997-02-11 1999-05-04 Sepracor Inc. Methods and compositions for treating allergic asthma and dermatitis using descarboethoxyloratadine
CA2315721C (en) * 1997-12-23 2008-08-12 Schering Corporation Composition for treating respiratory and skin diseases, comprising at least one leukotriene antagonist and at least one antihistamine
US6194431B1 (en) * 1998-04-14 2001-02-27 Paul D. Rubin Methods and compositions using terfenadine metabolites in combination with leukotriene inhibitors

Also Published As

Publication number Publication date
DE69931771T2 (de) 2006-10-12
CA2328074C (en) 2012-02-21
US20120149730A1 (en) 2012-06-14
ZA200005553B (en) 2001-05-17
US6194431B1 (en) 2001-02-27
NZ507762A (en) 2003-09-26
BR9909641A (pt) 2000-12-19
US8404715B2 (en) 2013-03-26
EP1071463A1 (en) 2001-01-31
PT1071463E (pt) 2006-10-31
ES2260910T3 (es) 2006-11-01
KR20010042655A (ko) 2001-05-25
AU763979B2 (en) 2003-08-07
AU3640999A (en) 1999-11-01
US6509353B1 (en) 2003-01-21
CY1106800T1 (el) 2012-05-23
JP2002511426A (ja) 2002-04-16
HU228035B1 (en) 2012-08-28
IL138993A0 (en) 2001-11-25
HUP0102239A3 (en) 2002-06-28
ATE328608T1 (de) 2006-06-15
CN1768749A (zh) 2006-05-10
NO20005147L (no) 2000-11-07
CN1305385A (zh) 2001-07-25
CA2328074A1 (en) 1999-10-21
DK1071463T3 (da) 2006-09-25
IL138993A (en) 2011-01-31
DE69931771D1 (de) 2006-07-20
US20030083343A1 (en) 2003-05-01
WO1999052554A1 (en) 1999-10-21
KR100686297B1 (ko) 2007-02-23
EP1707216A1 (en) 2006-10-04
PL343526A1 (en) 2001-08-27
NO20005147D0 (no) 2000-10-13
EP1071463B1 (en) 2006-06-07

Similar Documents

Publication Publication Date Title
IT1289160B1 (it) Compressa farmaceutica completamente rivestita per il rilascio controllato di principi attivi che presentano problemi di
AU2002346973A1 (en) Oral Dosage Form for Propiverine or its Pharmaceutically Acceptable Salts with an Extended Release of the Active Ingredient
AR030190A1 (es) Una pirimidinona o una sal farmaceuticamente aceptable de la misma, composicion farmaceutica que la comprende, uso de dicho compuesto en la fabricacion de medicamentos y procedimiento para prepararlo
HUP0000138A2 (hu) Szabályozott hatóanyag-leadású opioid analgetikumokat tartalmazó gyógyászati készítmények
HUP0102239A2 (hu) Terfenadin metabolitokat és leukotrién inhibitorokat tartalmazó gyógyásszati készítmények
HUP0102472A2 (hu) Nitrogén-oxid szintáz inhibitorként alkalmazható amidinoszármazékok, eljárás az előállításukra és a vegyületeket tartalmazó gyógyászati készítmények
EE05074B1 (et) Sulfoonamiid- ja sulfamiidasendatud imidasokinoliinid, nende kasutamine raviks ja neid sisaldavad farmatseutilised preparaadid
AU2002210952A1 (en) Preventives or remedies for psoriasis containing as the active ingredient IL-6 antagonist
NO2012019I1 (no) Kombinasjon av flutikason og formoterol, eller hvilket som helst farmasøytisk akseptabelt salt ellerderivat derav som er beskyttet ved basispatentet, inkludert kombinasjonen av flutikasonpropionat og formoterolfumarat.
MA27265A1 (fr) Formulations d'agoniste opioide a antagoniste liberable et sequestre
ES2133785T3 (es) Inhibidores de metaloproteinasas.
HUP0203028A2 (hu) Tolterodint tartalmazó gyógyszerkészítmény és alkalmazása
NO20062051L (no) Farmasoytisk virkestoffinneholdende formulering med belegg
NO20015309L (no) 1- (P-tienylbenzyl)-imidazoler som anginotensin-(1-7) reseptoragonister, fremgangsmåte for fremstilling og anvendelse avde samme og farmasöytiske preparater som inneholder nevnteforbindelser
HUP0301305A2 (hu) Dopamin D2/D3 receptor agonisták alkalmazása fibromialgia kezelésére szánt gyógyászati készítmények előállítására
BR9911871B1 (pt) derivados de ácido fenoxiacético e composições farmacêuticas contendo os mesmos.
HUP9901794A2 (hu) Protonpumpa inhibitorok új beadási formája
EE05385B1 (et) LaiaspektrilisedÁ2-(asendatudÁamino)bensotiasoolsulfoonamiididÁkuiÁHIVÁproteaasiÁinhibiitorid,ÁnendeÁvalmistamismeetodÁjaÁkasutamineÁningÁfarmatseutilineÁkompositsioon
WO2003065987A3 (en) Granzyme b inhibitors
FR2784899B1 (fr) Agoniste, agoniste partiel ou antagoniste du recepteur 5-ht4 ou un sel pharmaceutiquement acceptable de ceux-ci pour utilisation dans la fabrication d'une composition pharmaceutique, y compris a usage veterinaire
HK1033281A1 (en) Oral medicinal preparations with reproducible release of the active ingredient gatifloxacin or its pharmaceutically suitable salts or hydrates
MA28267A1 (fr) Formulations orales d'agonistes du recepteur 5-ht, utilisations et methodes de traitement faisant intervenir celles-ci
AU2002330850A1 (en) Use of inhibitors of the abc drug transporter to increase the activity of anti-microbial agents
TW200420557A (en) Salt of 7-isoindoline-quinolonecarboxylic acid derivative, its hydrate and anti-bacterially pharmaceutical composition comprising the same as active ingredient
FR2703249B1 (fr) Composition pharmaceutique ayant une activité analgésique contenant du naproxène.

Legal Events

Date Code Title Description
FH91 Appointment of a representative

Free format text: FORMER REPRESENTATIVE(S): S.B.G. & K. SZABADALMI UEGYVIVOEI IRODA, HU

Representative=s name: DANUBIA SZABADALMI ES JOGI IRODA KFT., HU

FH92 Termination of representative

Representative=s name: S.B.G. & K. SZABADALMI UEGYVIVOEI IRODA, HU

MM4A Lapse of definitive patent protection due to non-payment of fees